CLVT: Organic growth improved as the LS&H sale refocused the portfolio and reset 2026 guidance

What happened

Clarivate's third-quarter organic revenue returned to growth and adjusted earnings rose, even as reported revenue and cash flow stayed pressured by disposals and transactional declines. The LS&H unit was sold for $488.4M, and 2026 guidance now targets $320M–$340M in free cash flow.

Confirmed

Global impact / market context

Selling LS&H for $488.4M shrinks reported revenue but simplifies the business, so future sales and profits depend more on the remaining core. The $320M–$340M free cash flow target, which means cash left after running and investing in the business, is the key test of whether that slimmer portfolio works.

Analyst inference

Organic growth resuming suggests demand for Clarivate's remaining services is steady, while disposals and transactional declines cut reported numbers. Investors weighing the stock must decide whether a smaller, refocused company can reliably convert revenue into the guided free cash flow of $320M–$340M by 2026.

Analyst inference

What to watch

1. Watch whether reported revenue and cash flow keep shrinking because of disposals and transactional declines, even though organic revenue returned to growth in the quarter. Confirmed
2. Track progress toward the 2026 free cash flow target of $320M–$340M, since hitting it would show the refocused portfolio can fund itself after the LS&H sale. Proposed
3. Watch whether organic growth holds as the smaller company laps the LS&H sale, because a slip would pressure revenue and the cash needed for the 2026 forecast. Analyst inference

Evidence

• Original source link unavailable